Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation

Bone Marrow Transplantation

Volumn 25, Issue 4, 2000, Pages 401-404

  Andreani, M ^a   Nesci, S ^a   Lucarelli, G ^a   Tonucci, P ^a   Rapa, S ^a   Angelucci, E ^a   Persini, B ^a   Agostinelli, F ^a   Donati, M ^a   Manna, M ^a  

^a Ospedale di Muraglia   (Italy)

Author keywords

Persistent mixed chimerism after BMT

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; HEMOGLOBIN A;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHILD; CHIMERA; FEMALE; GRAFT REJECTION; HOST CELL; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PRIORITY JOURNAL; RISK; SURVIVAL; THALASSEMIA;

EID: 0033996420     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702151     Document Type: Article

References (16)

1. Hill RS, Petersen FB, Storb R et al. Mixed hematologic chimerism after allogenic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811-816.
2. Andreani M, Manna M, Lucarelli G et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 87: 3494-3499.
3. Lucarelli G, Clift R, Galimberti M et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999; 93: 1164-1167.
4. Lucarelli G, Galimberti M, Giardini C et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann NY Acad Sci 1998; 850: 270-275.
5. Sharabi Y, Abraham VS, Sykes M, Sachs D. Mixed allogeneic chimerism prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance. Bone Marrow Transplant 1992; 9: 191-197.
6. Slavin S, Nagler A, Napastek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
7. Dentamaro T, Cudillo L, Picardi A et al. Allogenic stem cell transplantation after non-myeloablative conditioning for poor risk patients with hematologic malignancies. Bone Marrow Transplant 1998; 21 (Suppl. I): 115.
8. Nesci S, Manna M, Andreani M et al. Mixed chimerism in thalassemic patients after bone marrow transplantation. Bone Marron Transplant 1992; 10: 143-147.
9. Smith AJ, Martin P, McFarland C et al. Evaluation of engraftment in the stem cell transplant setting by PCR DNA amplification and analysis of variable number tandem repeat loci. ASHI Quart 1998; 22: 3-9.
10. Petz LD, Yam P, Wallace RB et al. Mixed hematopoietic chimerism following bone marrow transplantation for hematologic malignancies. Blood 1987; 70: 1331-1337.
11. Bertheas MF, Lafage M, Levy P et al. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. Blood 1991; 78: 3103-3107.
12. Huss R, Deeg H, Gooley T et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 1996; 18: 767-776.
13. Aker M, Kapelushnik J, Pugatsch T et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major. J Pediatr Hematol Oncol 1998; 20: 145-148.
14. Collins RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
15. Elwood E, Larsen C, Maurer D et al. Microchimerism and rejection in clinical transplantation. Lancet 1997; 349: 1358-1360.
16. Flake A, Zanjani E. In utero hematopoietic stem cell transplantation. JAMA 1997; 278: 932-937.